SkyView Investment Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

SkyView Investment Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,936	Closed	-$540K	–	259
2026 Q1	$540K	Sell	1,936 -12	-0.6%	-$3.46K	0.07%	185
2025 Q4	$590K	Sell	1,948 -51	-3%	-$15.9K	0.07%	186
2025 Q3	$561K	Sell	1,999 -23	-1%	-$6.26K	0.07%	189
2025 Q2	$493K	Sell	2,022 -8	-0.4%	-$1.89K	0.07%	202
2025 Q1	$494K	Buy	2,030 +172	+9%	+$51.7K	0.07%	200
2024 Q4	$610K	Buy	+1,858	New	+$631K	0.1%	178
2023 Q3	–	Sell	-2	Closed	-$1K	–	612
2023 Q2	$1K	Buy	2 +1	+100%	+$407	﹤0.01%	632
2023 Q1	$0	Buy	+1	New	+$468	﹤0.01%	666
2022 Q1	–	Sell	-2,267	Closed	-$3K	–	586
2021 Q4	$3K	Buy	+2,267	New	+$1.7M	﹤0.01%	551

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

SkyView Investment Advisors's BIO Position: Q2 2026 in Review

SkyView Investment Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 1,936 shares — an estimated $540K sold.

SkyView Investment Advisors first reported a position in BIO in Q4 2021 and held it in 9 quarters. The position peaked at $610K in Q4 2024. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

SkyView Investment Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
SkyView Investment Advisors sold 1,936 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $540K.
SkyView Investment Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and held it in 9 quarters.
SkyView Investment Advisors's Bio-Rad Laboratories Class A position peaked at $610K in Q4 2024.
399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on SkyView Investment Advisors's 13F filing for Q2 2026, filed 15 Sep 2026.